期刊文献+

乳腺癌改良根治术中保留肋间臂神经的临床研究

Clinical study of intercostobrachial nerve reservation in radical resection of breast cancer
下载PDF
导出
摘要 目的探讨在乳腺癌改良根治术中保留肋间臂神经(ICBN)的可行性及其临床意义。方法在56例乳腺癌改良根治术中施行保留肋间臂神经手术,其中完整保留肋间臂神经38例,切除肋间臂神经18例。结果保留肋间臂神经38例与切除肋间臂神经18例术后患侧上臂内侧及腋部皮肤感觉异常比较,差异有统计学意义(P<0.01)。术后平均随访16个月,56例均未见局部复发。结论在乳腺癌改良根治术中通过手术技巧的改进,保留肋间臂神经是可行的,亦是必要的,它保存了患侧上臂内侧及腋部皮肤的感觉功能,提高患者生活质量。 Objective To investigate the clinical significance of intercostobrachial nerve reservation in radical resection of breast cancer. Methods 56 patients were under-went radical resection of breast cancer, the intercostobrachial nerve was reserved in 38 cases, and resected in 18 cases. Results Comparing esthesiodermia of internal upper arm and axilla in two groups:the intercostobrachial nerve was reserved (n = 38 ) in experimental group, and resected in control group (n = 18 ) , The differences between two groups were statistically significant(P〈0. 01). There were no focal tumor recurrence after a mean 16 flow-up. Conclusion Preserving inter-costobrachial nerve is feasible and necessary, with the improvement of surgical skills in radical resection. It keeped normal skin sensory function of internal upper arm. and enhanced the quality of life after operation.
出处 《中国实用医药》 2008年第23期54-55,共2页 China Practical Medicine
关键词 乳腺癌 改良根治术 肋间臂神经 Breast cancer Modifiedradical resection Intercostobrachial nerve
  • 相关文献

参考文献4

二级参考文献14

  • 1张斌.乳腺癌手术中医源性损伤的防治[J].中国实用外科杂志,1996,16(8):464-465. 被引量:15
  • 2[1]Defriend DJ, Howell A, Nicholson RI et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res, 1994, 54 (2) :408
  • 3[2]Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha- [9- (4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl] estra-l,3,5, (10)-triene-3, 17-beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res, 2001, 61 (18) :6739
  • 4[3]Wakeling AE, Dukes M, Bavler J, et al. A potent specific pure antiestrogen with clinical potential. Cancer Res, 1991, 51(15):3867
  • 5[4]Wakeling AE. Similarities and distinctions in the mode of action of different classes of antiestrogens. Endocr Relat Cancer, 2000, 7(1) :17
  • 6[5]Osborne CK, Coronado H EB, Hildenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst,1995, 87 (10) :746
  • 7[6]Osborne CK, Jarman M, Mcague R, et al. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.Cancer Chemother Pharmacol, 1994, 34 (2) :89
  • 8[7]Howell A, Defriend D, Robertson J, et al. Response to a specific antiestrogen (ICI 182, 780) in tamoxifen-resistant breast cancer. Lancet, 1995, 345 (8941) :29
  • 9[8]Howell A, Defriend D, Robertson J, et al. Pharmacokinetics,Pharmacological, and antitumor effects of the specific anti-oestrogen ICI 182, 780 in women with advanced breast cancer. Br J Cancer, 1996, 74 (2) :300
  • 10[9]Mauriac L, Pippen J. E, Quaresma J, et al. Fulvestrant(FaslodexTM ) verses anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials. European Journal of Cancer, 2003, 39 (9):1228

共引文献166

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部